RESEARCH, IN CONTEXT

Urolithin A: promising findings, important limits

Read the main outcomes and the secondary findings before accepting a mitochondrial-health headline.

Published November 7, 2026 · Source-researched editorial; no independent clinician review.

What one randomized trial found

A 2022 trial randomized 66 adults aged 65–90 to urolithin A or placebo for four months. Most participants were women and all were White. The primary measures—six-minute walking distance and maximal ATP production in hand muscle—did not improve significantly compared with placebo.

Some secondary muscle-endurance results favored supplementation at two months. At four months, the placebo group also improved and the between-group endurance differences were no longer significant. Some biomarkers changed. This is more nuanced than saying the trial proved an overall functional or longevity benefit.

Why context matters

The study was small, short and included manufacturer-affiliated researchers. That does not invalidate the work; it makes replication and careful reading especially valuable. Short-term tolerability is not proof of safety for everyone or of long-term lifespan extension.

Our editorial interpretation: an interesting research area with unanswered questions. The findings do not establish that healthy adults in their 40s should buy the product or expect the same results.

A sensible comparison

Timeline sells urolithin A products. The link is ordinary and informational. Read the exact formulation, serving instructions, ongoing cost and returns. Ask whether a product matches the intervention studied rather than assuming every product using the same ingredient name is equivalent.

Discuss suitability with a healthcare professional if you take medicines or have health conditions. Protect time and budget for appropriate strength training, nourishment and care before considering an optional supplement.

Original source and next step

• 2022 JAMA Network Open randomized trial ↗
• Supplement comparison worksheet ↗